SCHIZOFRENIA

Principal Investigators

Miquel Bernardo

Full professor

Schizophrenia

Research team

 

Miquel Bioque

Medical Assistant Professor

 

Rosa Catalan

Medical Assistant Professor

 

Clemente Garcia

Medical Assistant Professor

 

Gisela Mezquida

Medical Assistant Professor

 

Eduardo Parellada

Medical Assistant Professor

 

Rafael Penades

Medical Assistant Professor

 

Merce Torra

Medical Assistant Professor

 

Silvia Amoretti

Postdoctoral researcher

Research Interest

 

This programme focuses on schizophrenia and related disorders, including clinical care, research and teaching. The research is centred on the study of first-episodes, early onset, resistant and chronic schizophrenia. The main lines include neuroimaging, genetics, neurobiology and molecular psychiatry, neuropsychology, psychometric evaluation, psychopharmacology, psychoeducation and physical health.

Technologies & Methods

 

  • Functional and structural neuroimaging techniques.
  • Genetic and molecular biological techniques.
  • Psychometric evaluation.

Featured Projects

 

    • Biomarkers of synaptic loss, neuronal damage and inflammation in cerebrospinal fluid (CSF) and peripheral blood in patients with a first psychotic episode. Instituto de Salud Carlos III. Ministerio de Economía y competitividad. PI20/01006. Miquel Bioque i Miquel Bernardo

 

    • Cellular, molecular, genetic and cognitive-behavioral characterization of the antiapoptotic effect of clozapine and glutamate inhibitors in a postnatal ketamine animal model of schizophrenia. Fundació Clínic per a la recerca Biomèdica. FCRB_PB2_2018. Eduardo Parellada

 

    • Identificación y caracterización del valor predictivo de la reserva cognitiva en el curso evolutivo y respuesta en terapéutica en personas con un primer episodio psicótico. Departament de Salut. Generalitat de Catalunya. SLT006/17/00345. Miquel Bernardo

 

    • La permeabilidad intestinal como causa de inflamación crónica de bajo grado en pacientes con esquizofrenia: relación con la dieta, el síndrome metabólico y la gravedad de la enfermedad. Instituto de Salud Carlos III. Ministerio de Economía y comeptitividad. PI17/00246 FIS. Belen Arranz

 

    • Rehabilitación cognitiva en la esquizofrènia: variación genètica en los genes BDNF (Val66Met) y COMT (Val158Met) como posible modulador de la respuesta al tratamiento. Instituto de Salud Carlos III. Ministerio de Economía y competitividad. PI17/00872 FIS. Rafael Penades

Featured Publications

 

    • Gassó, P., Arnaiz, J. A., Mas, S., Lafuente, A., Bioque, M., Cuesta, M. J., Díaz-Caneja, C. M., García, C., Lobo, A., González-Pinto, A., Parellada, M., Corripio, I., Vieta, E., Castro-Fornieles, J., Mané, A., Rodríguez, N., Boloc, D., Saiz-Ruiz, J., Bernardo, M., & PEPs Group (2020). Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period. Journal of Psychopharmacology (Oxford, England), 34(5), 514–523. https://doi.org/10.1177/0269881120903462

 

    • García-Rizo, C., Bioque, M., Mezquida, G., Amoretti, S., Cuesta, M. J., Díaz-Caneja, C. M., Mas, S., Lobo, A., González-Pinto, A., Fraguas, D., Corripio, I., Vieta, E., Baeza, I., Bergé, D., Fernandez-Egea, E., Garriga, M., Bernardo, M., Parellada, E., Meseguer, A., … Selva-Vera, G. (2020). Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study. Schizophrenia Research, 218, 292–294. https://doi.org/10.1016/j.schres.2019.12.030

 

    • Bioque, M., Parellada, E., García-Rizo, C., Amoretti, S., Fortea, A., Oriolo, G., Palau, P., Boix-Quintana, E., Safont, G., & Bernardo, M. (2020). Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study. European Psychiatry, 63(1), e71. https://doi.org/10.1192/j.eurpsy.2020.72

 

    • Mas, S., Boloc, D., Rodríguez, N., Mezquida, G., Amoretti, S., Cuesta, M. J., González-Peñas, J., García-Alcón, A., Lobo, A., González-Pinto, A., Corripio, I., Vieta, E., Castro-Fornieles, J., Mané, A., Saiz-Ruiz, J., Gassó, P., Bioque, M., Bernardo, M., & Group, Pep. (2020). Examining Gene–Environment Interactions Using Aggregate Scores in a First-Episode Psychosis Cohort. Schizophrenia Bulletin, 46(4), 1019–1025. https://doi.org/10.1093/schbul/sbaa012

 

    • Mas, S., Gassó, P., Rodríguez, N., Cabrera, B., Mezquida, G., Lobo, A., González-Pinto, A., Parellada, M., Corripio, I., Vieta, E., Castro-Fornieles, J., Bobes, J., Usall, J., Saiz-Ruiz, J., Contreras, F., Parellada, E., Bernardo, M., & group, Pep. (2020). Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort. Acta Psychiatrica Scandinavica, 141(6), 541–552. https://doi.org/10.1111/acps.13131

 

    • Salagre, E., Grande, I., Vieta, E., Mezquida, G., Cuesta, M. J., Moreno, C., Bioque, M., Lobo, A., González-Pinto, A., Moreno, D. M., Corripio, I., Verdolini, N., Castro-Fornieles, J., Mané, A., Pinzon-Espinosa, J., Bonnin, C., Bernardo, M., & Group, P. (2020). Predictors of Bipolar Disorder Versus Schizophrenia Diagnosis in a Multicenter First Psychotic Episode Cohort: Baseline Characterization and a 12-Month Follow-Up Analysis. Journal of Clinical Psychiatry, 81(6), 19m12996. https://doi.org/10.4088/JCP.19m12996

 

    • Amoretti, S., Cabrera, B., Torrent, C., Bonnín, C. del M., Mezquida, G., Garriga, M., Jiménez, E., Martínez-Arán, A., Solé, B., Reinares, M., Varo, C., Penadés, R., Grande, I., Salagre, E., Parellada, E., Bioque, M., Garcia-Rizo, C., Meseguer, A., Anmella, G., … Bernardo, M. (2019). Cognitive Reserve Assessment Scale in Health (CRASH): Its Validity and Reliability. Journal of Clinical Medicine, 8(5), 586. https://doi.org/10.3390/jcm8050586

 

    • Bioque, M., Mas, S., Costanzo, M. C., Cabrera, B., Lobo, A., Gonzalez-Pinto, A., Rodriguez-Toscano, E., Corripio, I., Vieta, E., Baeza, I., Ibanez, A., Gutierrez Fraile, M., Cuesta, M. J., Mezquida, G., Lafuente, A., Bernardo, M., Amoretti, S., Meseguer, A., Lopez, G., … GRP, Pep. (2019). Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis. European Neuropsychopharmacology, 29(6), 786–794. https://doi.org/10.1016/j.euroneuro.2019.04.005

 

    • Ferraro, L., La Cascia, C., Quattrone, D., Sideli, L., Matranga, D., Capuccio, V., Tripoli, G., Gayer-Anderson, C., Morgan, C., Sami, M. B., Sham, P., de Haan, L., Velthorst, E., Jongsma, H. E., Kirkbride, J. B., Rutten, B. P. F., Richards, A. L., Roldan, L., Arango, C., … Di Forti, M. (2019). Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use. Schizophrenia Bulletin, 46(3), 517–529. https://doi.org/10.1093/schbul/sbz077

 

    • Penadés, R., López-Vílchez, I., Catalán, R., Arias, B., González-Rodríguez, A., García-Rizo, C., Masana, G., Ruíz, V., Mezquida, G., & Bernardo, M. (2018). BDNF as a marker of response to cognitive remediation in patients with schizophrenia: A randomized and controlled trial. Schizophrenia Research, 197, 458–464. https://doi.org/10.1016/j.schres.2017.12.002

Knowledge transfer & Innovation

 

  • Method for predicting the onset of extrapyramidal symptoms
    (EPS) induced by an antipsicotic-based treatment.
    AVCRI196